Monday, August 21, 2017
Company News: Page (1) of 1 - 03/14/12 Email this story to a friend. email article Print this page (Article printing at page facebook
Plandai Biotechnology, Inc. Director Dr. Ming Hu Study Demonstrates Significance of Bioavailability
CRS Hydrodynamic Process Delivers Up to 8 Times Improved Chemical Forms to Achieve Better Absorption Than Traditional Extracts
(March 14, 2012)

SEATTLE, WA -- (Marketwire) -- 03/14/12 -- Plandaí Biotechnology, Inc. (OTCBB: PLPL) director, Dr. Ming Hu, recently addressed his published study on the bioavailability of flavonoids and polyphenols and its importance on human health and nutrition.

Dietary polyphenols are derived from plants and are consumed in the forms of fruits, vegetables, spices, and herbs. Collectively they are a main source of antioxidants for humans and are responsible for a variety of biological activities, ranging from anti-aging and anticancer to lowering of blood cholesterol levels and improving bone strength. Millions of women also take a subclass of polyphenols called phytoestrogens to relieve symptoms associated with menopause.

Bioavailability is the body's ability to absorb various nutrients consumed. For most dietary antioxidants, less than five percent of the nutrients are actually absorbed, resulting in the need to consume massive dosages to achieve a clinical effect. Additionally, certain additives, including sugars and dairy, can neutralize the anti-oxidant properties. In the case of green tea, which has become hugely popular as a dietary supplement, you need to consume 8-10 cups a day; but if your green tea is sweetened, it may be useless. According to Dr. Hu's study, historically very little attention has been paid to increasing bioavailability. He asks the question, are these flavonoids and polyphenols as effective as people believe?

Typical polyphenols have oral bioavailability (mostly in animals) of 10% or less, and a range of 2-20% is quite common. For polyphenols to become bioavailable, the following barriers must be overcome: solubility, permeability, metabolism, excretion, target tissue uptake, and disposition.

Plandaí's proprietary CRS processing system is specifically designed to alter the stereochemical structure of the polyphenols into a ratio more readily absorbable by human tissue. For practical purposes, the converted phytonutrients should be five to eight times more bioavailable than traditional extracts, resulting in a clinical dose being more readily available and affordable as an additive to a variety of beverages, supplements and nutriceuticals.

Chief Executive Officer, Roger Duffield, commented, "We are at the forefront of developing enhanced bioavailable products which, we believe, can revolutionize the nutritional supplement and health drink marketplace. As more research is conducted, such as that done by Dr. Hu, people will be forced to examine what they consume and start to demand products that are based on science rather that slick marketing."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principal holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Plandai Biotechnology, Inc.
Tel: (425) 466-0212
Email: Email Contact

Copyright @ Marketwire

Page: 1

Related Keywords: Plandai Biotechnology, Africa, Marketwire, Inc., , Science, Women,
Related Sites:
Related Newsletter:

  • Medical Sector Contract Electronic Manufacturing Market shows lucrative growth CAGR of 8.8 % by 2022
  • BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker
  • Global Contrast Injector Market Will Reach USD 889.3 Million by 2022: Zion Market Research
  • Ascension Teams with Plug and Play Tech Center to Connect with Health and Wellness Startups
  • Global Sleep Apnea Devices Market to Grow at a CAGR of 7.8% by 2024 - Large Scale Benefits of Medical Devices is Driving Demand for Medical Platforms.

  • Gaucher Disease Market Is Anticipated To Witness Growth Owing To Increasing R&D Activities And Special Facility For Orphan Drugs Till 2021 | Million Insights
  • CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting
  • Astronauts Showcase Space Art Created with Childhood Cancer Patients
  • Three Grant Funding Opportunities for Brain Tumor Research Funding Open Today
  • argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines